Wednesday, July 2, 2008

Big Alzheimer Conference this month in Chicago


The Alzheimer’s Association International Conference on Alzheimer's Disease 2008 is coming up in Chicago on July 26-31. Among the more eagerly anticipated reports that will come out of the meeting will be preliminary results of the so-called GEM Study, which is looking at the putative protective effects that gingko biloba has against dementia. Also on the docket are preliminary results of a Phase III trial of gamma-secretase modulators (such as tarenflurbil) in the treatment of Alzheimer’s disease. I’ll let you know about any interesting developments coming out of this meeting.

at
Labels: , ,

2 comments:

Anonymous said...

Thanks. Please let us know what you think about beta amyloid vs. tau therapies

July 21, 2008 at 1:44 AM
Brian E. Moore, MD, MEd said...

Thanks for your comment, yoyoma. From what I heard at the most recent American Academy of Neurology meeting, the consensus is that tau deposition is downstream from amyloid deposition in Alzheimer's disease. So, going after amyloid therapeutically probably makes more sense. But there are dissenters from this opinion, and the jury is still out. I will report on the Alzheimer conference in Chicago next week. I'll not be there, but I'll monitor the website and let my loyal readers know about anything I see that might be of interest.

July 21, 2008 at 9:17 AM

Post a Comment

Subscribe to: Post Comments (Atom)

Neuropathology Blog is Signing Off

Neuropathology Blog has run its course. It's been a fantastic experience authoring this blog over many years. The blog has been a source...